ROG.SW Roche Holding AG (SIX) pre-market CHF360.00 14 Feb 2026: most active insight

ROG.SW stock opened pre-market at CHF360.00 on 14 Feb 2026 as traders scanned volume and earnings timing. The Swiss-listed Roche Holding AG (SIX: ROG.SW) shows market cap CHF286.56B, PE 22.42, and EPS CHF16.06. Volume is active at 1,172,436 versus an average of 1,157,045, marking the name among the most active on the SIX. We use Meyka AI real-time signals and sector context to connect today’s trading flow to valuations and short-term catalysts.

ROG.SW stock: price action and market flow

Pre-market trading shows Roche Holding AG (ROG.SW) at CHF360.00, up CHF0.30 or 0.08% from the prior close. The intraday range is CHF357.50–CHF361.80 and the 52-week high sits at CHF362.30. Volume is slightly above average at 1,172,436.00, a signal of continued interest among active traders.

One clear claim: short-term buyers are focused on momentum around the 50-day average CHF336.47 and the 200-day average CHF285.39. That gap underlines strength but leaves room for pullbacks into technical support near CHF340.20 (BB lower band).

ROG.SW stock: fundamentals snapshot and valuation

Roche’s financials show stable earnings with EPS CHF16.06 and a trailing PE 22.42. Key ratios include P/S 4.66, P/B 8.48, and dividend per share CHF9.70 (yield roughly 2.69%). Return on equity is strong at 41.23% and free cash flow per share is CHF14.91, supporting dividend coverage.

This claim links valuation to earnings: at current EPS a 18x multiple implies CHF289.08, while a 24x multiple implies CHF385.44. That defines a model-based fair-value range and frames upside and downside scenarios for traders and investors.

Meyka AI grade and ROG.SW stock forecast

Meyka AI rates ROG.SW with a score out of 100: 75.11 / 100 — Grade B+ — Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.

Meyka AI’s forecast model projects monthly CHF362.95 (implied upside +0.82% vs CHF360.00) and yearly CHF249.87 (implied downside -30.59%). Forecasts are model-based projections and not guarantees. Use them as scenario inputs, not certainties.

ROG.SW stock: technicals and trading levels

Momentum indicators show an RSI 64.37 and ADX 38.79, indicating a strong trend. Bollinger Bands are Upper 363.21, Middle 351.70, Lower 340.20. MACD histogram is slightly negative, suggesting near-term consolidation risk.

For active traders the priority levels are support CHF351.70 (BB middle / MA) and resistance CHF362.30–CHF363.21 (year high and BB upper). ATR is 6.86, useful for sizing stops around CHF6.50–CHF8.00 per share.

ROG.SW stock: catalysts, risks and sector context

Catalysts include Roche’s pipeline updates, diagnostics sales cycles, and the next earnings announcement on 2026-07-23. Healthcare sector momentum (average PE ~33.70) keeps Roche competitive but valuation multiples for peers vary.

Risks include margin pressure from R&D spend, FX shifts, and a debt-to-equity near 0.94. Roche’s diagnostics exposure can add cyclical revenue swings. Watch sector flows: healthcare has shown 3M performance +9.37% in recent data, which supports relative strength for ROG.SW.

Trading takeaway for most active ROG.SW stock participants

For most-active traders, Roche combines liquidity and clear technical levels. The stock trades with average volume 1,157,045.00 and live volume 1,172,436.00, so entry and exit are feasible without large slippage. Short-term setups favor momentum buys above CHF362.30 and pullback buys near CHF340.20.

Position sizing should respect Roche’s ATR CHF6.86 and the company’s dividend yield 2.69% for income-oriented trades. For longer holds, monitor updates to EPS and free cash flow, which drive valuation re-rates.

Final Thoughts

Key takeaways for ROG.SW stock: Roche trades at CHF360.00 pre-market on 14 Feb 2026 with active volume and a PE of 22.42, signalling fair valuation versus global healthcare peers. Meyka AI rates ROG.SW 75.11 / 100 (B+, BUY) after weighing sector trends, earnings quality, and cash flow metrics. Our model shows a near-term forecast of CHF362.95 (+0.82%) and a longer-run year projection of CHF249.87 (-30.59%). Traders should use technical levels CHF340.20 (support) and CHF362.30–CHF363.21 (resistance) to define risk. For investors, a reasonable price target range based on multiple scenarios is CHF290.00–CHF390.00, reflecting earnings sensitivity and Roche’s strong ROE 41.23%. Forecasts are model-based projections and not guarantees. Use Meyka AI’s tools and this data to shape trade plans and risk limits.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.